Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27775561 | 0.76 | SLC22A12 (0.43) | HCAR3SLC22A12RAB9AMEN1KMT2A | |
| SCHEMBL3472266 | 0.74 | KDM5A (0.47) | HCAR3SLC22A12MEN1KMT2AKDM4E | |
| SCHEMBL23535818 | 0.74 | HCAR3 (0.51) | HCAR3SLC22A12RAB9ANPC1MEN1 | |
| SCHEMBL29301478 | 0.72 | TDP1 (0.44) | HCAR3SLC22A12RAB9ANPC1MEN1 | |
| SCHEMBL3471615 | 0.72 | MEN1 (0.44) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL6301461 | 0.69 | SLC22A12 (0.47) | HCAR3SLC22A12RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27566384 | 0.68 | SLC22A12 (0.41) | SLC22A12RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2366504 | 0.66 | HPGD (0.49) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL20606579 | 0.64 | HCAR3 (0.46) | HCAR3RAB9ANPC1TDP1MITF | |
| SCHEMBL2733644 | 0.64 | MCL1 (0.41) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2044031-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | Bayer HealthCare AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006479-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | F2, TFPI, PLAT | HCAR3 1216/4885SLC22A12 4633/4885RAB9A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.